Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company emerged from the development stage in the quarter ended June 30, 2004, following the establishment of significant collaboration activities, specifically a second strategic alliance with Merck & Co., Inc. The company completed its Initial Public Offering (IPO) in June 2004, raising approximately $30 million in net proceeds.
Key Financial Metrics
| Financial Metric ($ in thousands) | Three Months Ended Sep 30, 2004 |
Nine Months Ended Sep 30, 2004 |
Nine Months Ended Sep 30, 2003 |
|---|---|---|---|
| Revenue | $1,367 | $1,632 | $74 |
| Net Loss | $(6,416) | $(26,954) | $(16,498) |
| Net Loss Attributable to Common Stockholders | $(6,416) | $(29,667) | $(18,264) |
| Net Loss Per Share (Basic & Diluted) | $(0.33) | $(3.14) | $(24.89) |
| Cash and Cash Equivalents (Sep 30, 2004) | $14,544 | ||
| Marketable Securities (Sep 30, 2004) | $30,393 | ||
| Total Current Assets (Sep 30, 2004) | $47,198 | ||
| Total Current Liabilities (Sep 30, 2004) | $6,640 | ||
| Long-Term Debt (Sep 30, 2004) | $6,591 | ||
| Accumulated Deficit (Sep 30, 2004) | $(57,305) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $74,000 in the nine months ended September 30, 2003, to $1,632,000 in the same period in 2004. This growth is driven by the amortization of upfront payments and cost reimbursements from the new ocular collaboration with Merck.
- Operating Expenses: Total operating costs and expenses rose from $16.6 million (9 months 2003) to $28.4 million (9 months 2004).
- R&D Expenses: Increased from $7.3 million to $19.4 million, primarily due to a $5.5 million license fee paid to Isis Pharmaceuticals, increased activity at the acquired Alnylam Europe subsidiary, and higher compensation costs.
- G&A Expenses: Increased from $4.7 million to $8.9 million, driven by stock-based compensation and infrastructure costs associated with becoming a public company.
- One-Time Items: The 2003 period included a $4.6 million charge for purchased in-process R&D related to the acquisition of Ribopharma AG, which is not present in the 2004 period.
- Liquidity: Cash and cash equivalents decreased from $23.2 million at year-end 2003 to $14.5 million at September 30, 2004, despite the $30 million IPO proceeds, due to significant cash usage in operations ($18.6 million) and investing activities ($35.5 million, largely for marketable securities and equipment).
Guidance, Outlook, and Risks
- Outlook: Management expects to incur significant additional losses over the next several years as R&D activities expand. The company believes existing resources will fund operations through at least the end of 2006.
- Collaborations: Future revenues are expected to be derived primarily from strategic alliances. Key partnerships include:
- Merck: A multi-year collaboration for ocular diseases (e.g., Age-Related Macular Degeneration). Alnylam received $2 million in license fees and $1 million in cost reimbursements.
- Isis Pharmaceuticals: A license agreement involving a $5 million upfront fee (partially paid) and potential milestone payments.
- Risks and Contingencies:
- Technology Risk: RNAi is an unproven therapeutic approach; no products have received regulatory approval.
- Capital Needs: The company requires substantial additional funding for clinical trials and commercialization. Failure to secure funding could force curtailment of operations.
- Intellectual Property: The company relies on third-party licenses (e.g., Max Planck, Isis). A key patent (Kreutzer-Limmer) is subject to opposition proceedings in Europe which could invalidate it.
- Regulatory: No drug applications have been submitted. The FDA has not established definitive policies for RNAi therapeutics.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $44.9 million in liquid assets (cash + marketable securities) to fund operations through 2006 given the high burn rate.
- Collaboration Terms: Review the specific milestones and payment triggers in the Merck and Isis agreements to assess future revenue certainty.
- Patent Status: Monitor the outcome of the European Patent Office opposition regarding the Kreutzer-Limmer patent, which is critical to the company's IP portfolio.
- Debt Covenants: Confirm compliance with the Lighthouse Capital Partners equipment line of credit covenants, which limit asset sales and dividends.
- Stock-Based Compensation: Assess the impact of future stock price fluctuations on non-cash compensation expenses, particularly for non-employee awards which are marked-to-market.